In addition, RGS16 serves a non-negligible role in tumorigenesis, especially in the progression of breast cancer, for which it may be a novel therapeutic target, and its expression levels are also a biomarker for the diagnosis and prognosis of pancreatic cancer, PDA, colorectal cancer and glioma; however, its expression has only been tested in relation to prognosis. This evidence concerns the gene RGS16 and familial pancreatic carcinoma.